In Switzerland, patients have been able to receive enzyme replacement therapy at home since 2004. This form of treatment improves quality of life and is supervised by specialized doctors.

Home therapy has now established itself nationwide and the majority of patients take advantage of this free offer. It is also part of regular healthcare internationally, for example in the USA and the UK.

To date, thousands of infusions have been successfully carried out at home in Switzerland. A continuous exchange with the treating doctor ensures that all medical information remains transparent and that the success of the therapy is optimized.

D/F/I

In Switzerland, the company Sciensus AG (formerly HTHC High Tech Home Care AG) specializes in home therapy for Fabry disease patients. Due to the close cooperation with the parent company Sciensus Pharma Services Ltd, a leading international healthcare provider based in the UK, patients benefit from many years of international experience and the associated safety of home therapy.

En Suisse, l'entreprise Sciensus AG (anciennement HTHC High Tech Home Care AG) s'est spécialisée dans le traitement à domicile des patients atteints de la maladie de Fabry. Thanks to its close collaboration with its parent company Sciensus Pharma Services Ltd, a prestataire de services de santé international de premier plan dont le siège est en Grande-Bretagne, les patients traités bénéficient d'une longue expérience internationale et de la sécurité qui en découle pour le traitement à domicile.

La società Sciensus AG (ex HTHC High Tech Home Care AG) si è specializzata in Svizzera sulla terapiadomiciliare dei pazienti affetti dalla malattia di Fabry. Grazie alla stretta collaborazione con la società madreSciensus Pharma Services Ltd, leader internazionale nel settore sanitario con sede nel Regno Unito, i pazienti beneficiano della pluriennale esperienza internazionale e della conseguente maggiore sicurezzanella terapia domiciliare.